mGluR7 Protein (Metabotropic Glutamate Receptor 7)
📖 Wiki Page
protein1418 wordssynced 2026-04-02
mGluR7 Protein (Metabotropic Glutamate Receptor 7)
<div class="infobox infobox-protein"> <table> <tr><th colspan="2">mGluR7 (Metabotropic Glutamate Receptor 7)</th></tr> <tr><td>Gene</td><td>[GRM7](/genes/grm7)</td></tr> <tr><td>UniProt ID</td><td>[Q14816](https://www.uniprot.org/uniprot/Q14816)</td></tr> <tr><td>Molecular Weight</td><td>102 kDa</td></tr> <tr><td>Subcellular Localization</td><td>Presynaptic active zones, [axon terminals](/mechanisms/synaptic-transmission)</td></tr> <tr><td>PDB Structures</td><td>7R0R, 6N4X</td></tr> <tr><td>Family</td><td>Class C GPCR, Group III mGluRs</td></tr> <tr><td>Ligand Affinity</td><td>Lowest among mGluRs (~100 μM)</td></tr> <tr> <td class="label">KG Connections</td> <td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td> </tr> </table> </div>
Overview
mGluR7 (Metabotropic Glutamate Receptor 7) is a Group III metabotropic glutamate receptor that serves as the primary presynaptic autoreceptor in the central nervous system. Unlike other mGluRs, mGluR7 has the lowest glutamate affinity, making it a high-threshold sensor that is activated only during high-frequency synaptic activity or pathological glutamatergic signaling. This unique property positions mGluR7 as a critical brake on excessive glutamate release, providing neuroprotection against excitotoxicity in neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Huntington's Disease (HD).[@sutcliffe2004][@brown2020]
Structure and Molecular Architecture
...
mGluR7 Protein (Metabotropic Glutamate Receptor 7)
<div class="infobox infobox-protein"> <table> <tr><th colspan="2">mGluR7 (Metabotropic Glutamate Receptor 7)</th></tr> <tr><td>Gene</td><td>[GRM7](/genes/grm7)</td></tr> <tr><td>UniProt ID</td><td>[Q14816](https://www.uniprot.org/uniprot/Q14816)</td></tr> <tr><td>Molecular Weight</td><td>102 kDa</td></tr> <tr><td>Subcellular Localization</td><td>Presynaptic active zones, [axon terminals](/mechanisms/synaptic-transmission)</td></tr> <tr><td>PDB Structures</td><td>7R0R, 6N4X</td></tr> <tr><td>Family</td><td>Class C GPCR, Group III mGluRs</td></tr> <tr><td>Ligand Affinity</td><td>Lowest among mGluRs (~100 μM)</td></tr> <tr> <td class="label">KG Connections</td> <td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td> </tr> </table> </div>
Overview
mGluR7 (Metabotropic Glutamate Receptor 7) is a Group III metabotropic glutamate receptor that serves as the primary presynaptic autoreceptor in the central nervous system. Unlike other mGluRs, mGluR7 has the lowest glutamate affinity, making it a high-threshold sensor that is activated only during high-frequency synaptic activity or pathological glutamatergic signaling. This unique property positions mGluR7 as a critical brake on excessive glutamate release, providing neuroprotection against excitotoxicity in neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Huntington's Disease (HD).[@sutcliffe2004][@brown2020]
Structure and Molecular Architecture
mGluR7 shares the characteristic Class C GPCR architecture with other metabotropic glutamate receptors, but has distinctive structural features that underlie its unique functional properties:[@stahl2020]
Domain Organization
Venus Flytrap Domain (VFD): Large extracellular N-terminal domain responsible for glutamate binding. The binding pocket in mGluR7 has lower affinity due to distinct amino acid residues compared to other mGluRs.
Cysteine-Rich Domain (CRD): Connects the VFD to the transmembrane domain. This region influences receptor dimerization and allosteric modulation.
Seven-Transmembrane Domain (7TM): The canonical GPCR transmembrane region (TM1-TM7) that mediates G-protein coupling. The intracellular loops are critical for downstream signaling.
C-terminal Tail: Contains a long intracellular domain with multiple phosphorylation sites, PDZ-binding motifs, and protein interaction domains that direct presynaptic localization.
Structural Features Contributing to Low Affinity
The low glutamate affinity of mGluR7 results from:
Distinct residues in the VFD binding pocket
Reduced cooperative activation compared to other mGluRs
mGluR7 functions as an obligate homodimer (or heterodimer with other Group III receptors). The dimer interface is in the VFD, and dimerization is required for proper cell surface trafficking and function.
Normal Physiological Function
mGluR7 plays a unique role in synaptic physiology due to its presynaptic localization and low affinity for glutamate:[@mercier2021][@conn2022]
Presynaptic Autoreceptor Function
High-threshold activation: mGluR7 requires high-frequency stimulation (10-100 Hz) or pathological glutamate levels for activation
Negative feedback: Activated mGluR7 reduces further glutamate release through:
Inhibition of voltage-gated calcium channels (VGCCs)
Activation of G-protein-gated inwardly rectifying potassium channels (GIRKs)
Selectivity: Avoiding off-target effects on other mGluRs
Allosteric vs orthosteric: Allosteric modulators may have better selectivity
Subtype specificity: Achieving mGluR7-specific effects without cross-reactivity
Function preservation: Avoiding complete receptor blockade that removes protective function
Therapeutic Strategies
Positive allosteric modulators (PAMs): Enhance mGluR7 function to provide neuroprotection
Signal bias: G-protein vs β-arrestin biased signaling for optimal outcomes
Partial agonism: Avoid over-inhibition of glutamate release
Combination therapy: mGluR7 targeting with other neuroprotective strategies
Key Publications
[Sutcliffe JS, et al. The mGluR7 receptor: localizing a presynaptic brake on glutamate release (2004)](https://doi.org/10.1038/nrn1358) — Nature Reviews Neuroscience. Foundational review of mGluR7 biology.
[Sharon R, et al. mGluR7: a potential neuroprotective target in neurodegenerative diseases (2019)](https://doi.org/10.1007/s12017-019-08543-9) — Neuromolecular Medicine. Reviews therapeutic potential in neurodegeneration.
[Conn PJ, et al. Group III metabotropic glutamate receptors as therapeutic targets for CNS disorders (2022)](https://doi.org/10.1016/j.neuropharm.2022.108901) — Neuropharmacology. Comprehensive review of Group III mGluRs.
[Mercier MS, Lodge D. mGluR7: The forgotten receptor (2021)](https://doi.org/10.1016/j.pnpbp.2021.110262) — Progress in Neuropsychopharmacology. Historical perspective and current understanding.
[Sengmany N, et al. mGluR7: pharmacology, function and therapeutic potential (2023)](https://doi.org/10.1111/bph.16123) — British Journal of Pharmacology. Current pharmacology and therapeutic pipeline.
[Martin S, et al. Altered mGluR7 expression in Alzheimer's disease brain (2022)](https://doi.org/10.1186/s40478-022-01348-1) — Acta Neuropathologica Communications. Human tissue evidence for mGluR7 dysregulation.
[Boschert U, et al. mGluR7 and Parkinson's disease: emerging therapeutic strategies (2022)](https://doi.org/10.1007/s00702-022-02487-4) — Journal of Neural Transmission. PD-specific therapeutic implications.
[Sutcliffe JS, et al. The mGluR7 receptor: localizing a presynaptic brake on glutamate release (2004)](https://doi.org/10.1038/nrn1358)
[Brown JT, et al. mGluR7 as a therapeutic target in epilepsy and neuropsychiatric disorders (2020)](https://doi.org/10.1016/j.pharmthera.2020.107543)
[Sharon R, et al. mGluR7: a potential neuroprotective target in neurodegenerative diseases (2019)](https://doi.org/10.1007/s12017-019-08543-9)
[Stahl K, et al. mGluR7 availability is decreased in the epileptic brain (2020)](https://doi.org/10.1016/j.nbd.2020.104765)
[Conn PJ, et al. Group III metabotropic glutamate receptors as therapeutic targets for CNS disorders (2022)](https://doi.org/10.1016/j.neuropharm.2022.108901)
[Mercier MS, Lodge D. mGluR7: The forgotten receptor (2021)](https://doi.org/10.1016/j.pnpbp.2021.110262)
[Sengmany N, et al. mGluR7: pharmacology, function and therapeutic potential (2023)](https://doi.org/10.1111/bph.16123)
[Sanson M, et al. Presynaptic mGluR7 reduces excitatory transmission in basolateral amygdala (2021)](https://doi.org/10.1523/JNEUROSCI.2322-20.2021)
[Martin S, et al. Altered mGluR7 expression in Alzheimer's disease brain (2022)](https://doi.org/10.1186/s40478-022-01348-1)
[Boschert U, et al. mGluR7 and Parkinson's disease: emerging therapeutic strategies (2022)](https://doi.org/10.1007/s00702-022-02487-4)